William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

University of Pennsylvania School of Medicine: Upjohn Award, 1979
Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

Research Funding

The vital role of BAFF in the development of SLE
NIH · R01AR050193 · May 16, 2006 – Aug 31, 2012 · Role: Principal Investigator
T CELL CYTOLYTIC ACTIVITY IN SLE
NIH · R01AR041006 · Aug 12, 1993 – Jun 30, 2002 · Role: Principal Investigator
POLYMORPHISM WITHIN T4/LEU3 AND SLE
NIH · R23AR036527 · Jan 1, 1986 – Jun 30, 1989 · Role: Principal Investigator

Media

Publications

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition. Lupus. 2021 Apr; 30(5):795-806.. View in PubMed
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 06; 80(6):727-738.. View in PubMed
Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice. J Transl Autoimmun. 2021; 4:100075.. View in PubMed
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021 Feb; 3(2):e122-e130.. View in PubMed
Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020 12; 24(12):1283-1302.. View in PubMed
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial. Lancet Rheumatol. 2020 Oct; 2(10):e613-e622.. View in PubMed
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Front Med (Lausanne). 2020; 7:303.. View in PubMed
Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF. Arthritis Res Ther. 2020 05 07; 22(1):106.. View in PubMed
Promotion of T Regulatory Cells in Mice by B Cells and BAFF. J Immunol. 2020 05 01; 204(9):2416-2428.. View in PubMed
Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF. Arthritis Rheumatol. 2020 02; 72(2):292-302.. View in PubMed